Viridian raises ~$359M via $250M convertible notes and $117M equity offering

Viridian Therapeutics, Inc.\DE

• Issued $250M aggregate principal of 1.75% Convertible Senior Notes due 2032; initial conversion price ~$24.65/share.
• Equity offering of 7,352,942 shares at $17.00/share, netting ~$117M.
• Combined net proceeds ~$359M; to repay Hercules Capital debt, fund thyroid eye disease franchise expansion, and R&D.
• Both offerings closed May 11, 2026; underwriters' over-allotments exercised in full.
• Notes are unsecured, mature May 15, 2032, with semi-annual interest starting Nov 15, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.